AstraZeneca and Pozen, Inc. received approval from the FDA for Vimovo (naproxen and esomeprazole magnesium) delayed-release tablets for the relief of symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. Vimovo is a fixed-dose combination of enteric-coated naproxen, a pain-relieving non-steroidal anti-inflammatory drug (NSAID), and immediate-release esomeprazole, ...